Can Entresto be used in patients with kidney failure?
Entresto (sacubitril/valsartan) is used for heart failure, but kidney function matters because the drug can worsen renal function in some people and can raise potassium levels. In practice, clinicians typically use it with caution in anyone with chronic kidney disease or acute kidney injury, starting/continuing only if the expected heart-failure benefit outweighs the kidney risks.
What does “renal failure” mean here—dialysis, severe CKD, or acute kidney injury?
Risks and dosing decisions differ depending on which situation applies:
- Severe chronic kidney disease: Higher baseline risk for hyperkalemia and further kidney decline.
- Acute kidney injury (AKI): Risk can be higher because kidney function is unstable; clinicians may hold or adjust therapy if creatinine rises or potassium increases.
- Dialysis/end-stage kidney disease: Entresto still may be considered in selected cases, but the evidence base and monitoring approach depend on local guidance and patient specifics.
What kidney-related side effects should patients watch for?
Patients (and clinicians) focus on two main problems:
- Rising creatinine / worsening kidney function after starting or increasing dose
- High potassium (hyperkalemia)
Both can be dangerous. Hyperkalemia can cause weakness or heart rhythm problems, while a meaningful creatinine rise can signal reduced renal perfusion or drug-related effects.
What monitoring is usually done when someone with kidney disease takes Entresto?
Common monitoring includes:
- Blood creatinine and estimated glomerular filtration rate (eGFR) to track kidney function
- Serum potassium to detect hyperkalemia early
- Blood pressure (because low blood pressure can reduce kidney perfusion)
If labs worsen soon after starting Entresto or changing the dose, clinicians often reassess dose, timing, and contributing factors (dehydration, nonsteroidal anti-inflammatory drugs, other medicines that raise potassium, etc.).
What drug interactions raise the risk of renal failure or hyperkalemia with Entresto?
Entresto’s valsartan component adds to the risk of high potassium and kidney strain when combined with other potassium-raising or kidney-stressing therapies, for example:
- Other renin-angiotensin system blockers (ACE inhibitors, other ARBs)
- Potassium supplements
- Potassium-sparing diuretics (such as spironolactone or eplerenone)
- Some anti-inflammatory drugs (notably NSAIDs), especially in people with poor kidney function
Because many heart-failure regimens are polypharmacy, medication review is usually essential when renal function is already impaired.
When should Entresto be held or adjusted?
Clinicians commonly consider holding or reducing Entresto if:
- Potassium rises above safe thresholds
- Creatinine increases substantially after starting or dose escalation
- The patient develops acute illness that reduces effective circulation (for example, dehydration) or worsening renal perfusion
The exact cutoffs and decisions depend on the patient’s baseline kidney function and local prescribing guidance.
Does Entresto worsen kidney function long-term in heart failure?
In heart failure care, kidney outcomes are often mixed because people with heart failure can experience kidney worsening even without medication changes. The key clinical question is whether kidney function stabilizes and heart-failure outcomes improve overall. That balance depends on baseline renal status, blood pressure, volume status, and potassium monitoring.
What alternatives exist if Entresto isn’t safe with kidney failure?
If renal function or potassium limits Entresto use, heart-failure clinicians may consider other guideline-based options, adjusting for kidney disease risk. Which alternatives fit best depends on the heart-failure type (HFrEF vs HFpEF) and the patient’s lab profile and blood pressure.
---
Source
No DrugPatentWatch.com or other specific sources were provided with your question, so I did not cite external material. If you share the exact renal-failure scenario (e.g., dialysis vs eGFR range vs creatinine/AKI) and whether you’re asking about dosing, safety, or monitoring, I can tailor the answer to that situation.